Monograph Details
|
|
Neoplasms
> Cytotoxic antibiotics
|
|
IDAMYCIN |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Anthracycline |
| Generic Name |
|
Idarubicin HCl 20mg/vial; lyophilized pwd for IV infusion after reconstitution. |
| Also |
|
• IDAMYCIN PFS
|
| Indications |
|
Acute myeloid leukemia. |
| Children |
|
Not recommended. |
| Adults |
|
Give by slow IV infusion (over 10–15 minutes). 12mg/m2 daily for 3 days (in combination with cytarabine). May give 2nd course if needed; if toxicity develops after 1st course, delay until resolved; reduce dose by 25%. Hepatic and renal impairment: consider reduce dose. |
| Precautions |
|
Pre-existing bone marrow suppression. Cardiovascular disease. Thoracic irradiation. Previous anthracycline therapy at high cumulative doses. Renal or hepatic impairment. Monitor CBCs, cardiac, renal and hepatic function prior to and during treatment. Avoid extravasation. Elderly. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Adverse Reactions |
|
Myelosuppression, GI upset, mucositis, abdominal pain, alopecia, rash, inj site reactions, hepatotoxicity, renal toxicity, cardiotoxicity (eg, CHF, arrhythmias, chest pain, MI, asymptomatic declines in LVEF), hyperuricemia. |
| How Supplied |
Single-dose vials—1
PFS: Single-dose vials (5mL, 10mL, 20mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
